Cell and gene therapy are important concepts and approaches in modern medicine because they are employed in gene control, cell-cell interactions, regenerative ability, and remodelling.
The global cell and gene therapy market size was valued at US$ 6,020.0 million in 2017 and is expected to exhibit a CAGR of 21.9% over the forecast period (2018 – 2026).
Request FREE Sample: https://www.coherentmarketinsights.com/insight/request-sample/2475
Increasing prevalence of cardiovascular disease and cancer is expected to propel growth of cell and gene therapy market
Gene therapy tries to influence the course of many inherited and acquired problems at the genetic level, whereas cell therapy focuses on diseases at the cellular level, such as by restoring a specific cell population or by employing cells as therapeutic carriers. The high prevalence of cardiovascular illness is predicted to boost demand for cell and gene therapy, resulting in market expansion. According to the World Health Organization (WHO), 17.9 million people died worldwide in 2016 owing to cardiovascular disease, accounting for 31% of all deaths According to the World Health Organization, cancer was the second biggest cause of illness and mortality in 2012, with roughly 14 million new cases reported, and 8.8 million deaths worldwide. Furthermore, according to WHO, the number of new cases is predicted to increase by roughly 70% by 2030.
Furthermore, over the projection period, the adoption of effective guidelines is likely to move the global cell and gene therapy market forward. For example, from 1998 to 2018, the US Food and Drug Administration (FDA) published roughly 28 recommendations documents on various cell and gene therapies.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/cell-and-gene-therapy-market-to-surpass-us-354-billion-by-2026-1275
However, various development challenges, such as safety and efficacy concerns, extensive clinical study procedures, a strict regulatory environment, and expensive costs, are projected to limit cell and gene therapy acceptance, restricting market growth.
Increasing prevalence of neurological disorders in North America is expected to bolster the market growth
Because of the high prevalence of genetic illnesses, North America dominates the global cell and gene therapy market. According to the U.S. Pharmacist Journal, approximately 1.2 million adults are diagnosed with early symptoms of brain disorders each year, with Alzheimer’s disease accounting for 21% of these cases, and the total number of new cases of Parkinson’s disease and traumatic brain injuries in the United States is around 135 million.
Furthermore, as research and development activities expand, demand for cell and gene therapy is likely to rise. According to the Catalyst study, there were around 289 innovative cell and gene therapies in development in December 2018 for a variety of disorders, with around 111 medications for cancer and about 28 medications for cardiovascular disease. These drugs are either in clinical trials or waiting to be approved by the Food and Drug Administration in the United States (FDA).
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2475
Key Players
The main players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837